ascendis pharma glp-1 receptor agonist weight management diabetes treatments The Landscape Of GLP-1 Receptor Agonists In Diabetes And Obesity Treatment effect free approach to reducing appetite Ozempic maker Novo Nordisk is

December 2, 2025: Modest Growth for Ozempic Gastroparesis MDL There are now 2,947 active lawsuits in the MDL focused on claims involving GLP-1 drugs and intestinal conditions like gastroparesis

Recently, two novel therapeutic classes have emerged: sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists

In addition, fat can infiltrate muscles, causing them to be weaker

Below are the factors to consider when determining which option might be best suited for you

While the LIVE and FIGHT trials explored their effects on heart failure with reduced ejection fraction (HFrEF), the STEP-HFpEF trial demonstrated that GLP-1RAs improve HFpEF outcomes by reducing symptoms, physical limitations, and body weight [9]